AHA/ACC guidance formalizes hypertension management in pregnancy and emphasizes cardiovascular risk stratification using the ...

Advanced cardiovascular-kidney-metabolic (CKM) syndrome stage, especially stages 3 and 4, is associated with increased cancer risk.

The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.

The American Academy of Physician Associates and the PA Education Association plan to challenge the ruling in federal court.

Chronic oral glucocorticoid use is linked to increased mortality, with risk rising alongside higher cumulative exposure and daily doses.

HealthDay News — For patients with chronic kidney disease (CKD), cognitive impairment (CI) is associated with worse outcomes, according to a study published in the May issue of Kidney International ...

A new guideline for acute pulmonary embolism developed by 10 major specialty societies introduces a novel PE clinical ...

Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.

Treatment with a once-daily pill containing 3 low-dose antihypertensive agents is associated with a lower incidence of recurrent stroke.

Machine learning models can predict the risk for developing moderate-to-severe persistent asthma and allergic rhinitis in children with early-life AD.

A new proposal could make it easier for many patients to access breakthrough medical devices through Medicare.

Survodutide, a dual GLP-1 and glucagon receptor agonist, significantly reduced body weight in adults with obesity in the SYNCHRONIZE-1 trial.